US · CRON
Cronos Group Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Stayner, ON M5V 2H1
- Website
- thecronosgroup.com
Price · as of 2025-12-31
$2.64
Market cap 1.02B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.03 | +1,226.89% |
| Intrinsic Value(DCF) | $1.63 | -38.26% |
| Graham-Dodd Method(GD) | $2.54 | -3.64% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | $0.00 | ||||
| 2015 | $0.20 | ||||
| 2016 | $0.20 | $0.80 | |||
| 2017 | $9.32 | $175.38 | $419.77 | $0.30 | $0.00 |
| 2018 | $21.74 | $41.85 | $131,996.12 | $0.20 | $0.00 |
| 2019 | $5.81 | $82.80 | $41,296.80 | $17.00 | $269.10 |
| 2020 | $10.34 | $41.73 | $84,112.30 | $3.32 | $0.00 |
| 2021 | $3.09 | $28.52 | $2,654.71 | $0.00 | $0.00 |
| 2022 | $1.93 | $29.92 | $1.35 | $0.79 | $0.00 |
| 2023 | $1.99 | $33.23 | $1.53 | $1.81 | $0.00 |
| 2024 | $1.99 | $33.42 | $1.76 | $3.16 | $4.45 |
| 2025 | $2.63 | $35.03 | $2.45 | $2.54 | $0.00 |
AI valuation
Our deep-learning model estimates Cronos Group Inc.'s (CRON) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.03
- Current price
- $2.64
- AI upside
- +1,226.89%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.63
-38.26% upside
Graham-Dodd
$2.54
-3.64% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CRON | Cronos Group Inc. | $2.64 | 1.02B | +1,227% | -38% | -4% | — | — | 0.93 | 5.24 | -12.20 | — | 0.99 | 32.46% | -1.51% | -4.89% | 0.00% | -0.69% | 0.00% | 0.00 | — | 19.59 | 18.88 | 52.68 | -12227.00% | 6440.00% | -9734.00% | 0.01% | 0.55 | 0.06% | 0.00% | — | 0.98% | -62.50 | 1207.50 | 0.95 | 12.80 |
| AMPH | Amphastar Pharmaceuticals… | $20.23 | 929.61M | +167% | -56% | -25% | -32% | — | 1.25 | 1.36 | 5.01 | — | 4.41 | 49.46% | 19.50% | 13.63% | 0.00% | 13.00% | 0.00% | 0.06 | 5.51 | 4.02 | 2.70 | -0.82 | -3366.00% | -165.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 63.32% | 5.32 | — | 1.04 | 2.35 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| COLL | Collegium Pharmaceutical,… | $41.67 | 1.32B | +93% | +451% | -64% | +46% | 20.98 | 4.37 | 1.69 | 4.41 | — | -2.57 | 59.35% | 23.01% | 8.05% | 23.70% | 14.73% | 3.79% | 2.70 | 2.18 | 1.57 | 1.36 | 1.47 | -699.00% | 2362.00% | 6111.00% | 24.84% | 0.75 | 39.58% | 0.00% | 0.00% | 17.45% | 9.73 | 5.33 | 2.24 | 1.51 |
| EMBC | Embecta Corp. | $10.26 | 607.6M | +264% | -45% | — | -28% | 6.95 | -1.02 | 0.61 | 6.34 | 33.27 | -0.99 | 62.89% | 30.48% | 8.83% | -13.74% | 39.85% | 8.03% | -2.20 | 3.07 | 2.41 | 1.43 | 4.09 | 2090.00% | -380.00% | 81658.00% | 27.50% | 0.73 | 31.54% | 5.28% | 36.70% | 26.66% | 5.67 | 10.24 | 1.73 | 2.05 |
| IRMD | IRadimed Corporation | $103.53 | 1.32B | -46% | -36% | — | -72% | 33.89 | 7.51 | 8.90 | 26.33 | 305.02 | 7.79 | 76.94% | 29.99% | 26.26% | 24.31% | 59.56% | 20.20% | 0.00 | — | 8.84 | 7.38 | -2.29 | 1111.00% | 1171.00% | 22283.00% | 2.70% | 3.01 | 60.30% | 2.10% | 71.10% | 2.77% | 27.31 | 34.04 | 8.19 | 37.09 |
| NRIX | Nurix Therapeutics, Inc. | $15.97 | 1.38B | +65% | -49% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| PCRX | Pacira BioSciences, Inc. | $21.91 | 942.6M | +137% | -61% | -17% | -68% | 134.83 | 1.37 | 1.31 | 6.38 | — | 3.11 | 71.50% | 2.64% | 3.68% | 0.96% | 2.60% | 0.50% | 0.01 | 1.10 | 4.54 | 2.34 | -1.19 | -10744.00% | 363.00% | -2355.00% | 14.41% | 1.26 | 18.51% | 0.00% | 0.00% | 53.86% | 41.67 | 5.85 | 1.10 | 1.80 |
| PHAT | Phathom Pharmaceuticals, … | $12.56 | 979.85M | +275% | +76,266% | — | — | -3.78 | -1.91 | 4.77 | -4.45 | — | -1.91 | 87.09% | -91.36% | -126.35% | 63.97% | 57.00% | -69.41% | -0.01 | -2.35 | 1.73 | 1.58 | 0.80 | -4272.00% | 21693.00% | -3743.00% | -19.98% | -1.26 | 59.50% | 0.00% | 0.00% | 46.07% | -4.43 | -4.24 | 4.05 | -8.21 |
| RAPP | Rapport Therapeutics, Inc… | $29.03 | 1.06B | — | — | — | — | -2.27 | 0.58 | — | 1.62 | -2.27 | 0.58 | 0.00% | — | — | -55.97% | 98.09% | -33.30% | 0.00 | — | 35.34 | 34.82 | 0.71 | 10000.00% | — | 13331.00% | -37.74% | -7.39 | 79.40% | 0.00% | 0.00% | 0.00% | 1.51 | 1.87 | — | 10.97 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About Cronos Group Inc.
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
- CEO
- Michael Ryan Gorenstein
- Employees
- 459
- Beta
- 1.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.63 ÷ $2.64) − 1 = -38.26% (DCF, example).